Cytek Biosciences Earnings Call Transcripts
Fiscal Year 2026
-
Revenue grew 1% to $201.5M in 2025, outpacing a declining market and expanding global reach. Product innovation, especially Aurora Evo, and recurring revenue from services and reagents drive growth. APAC and clinical markets are key priorities for 2026.
-
A leading cell analysis company reported $201 million in 2024 revenue, driven by market share gains, product innovation, and global expansion. Growth is expected to accelerate through 2026, supported by new product launches, increased reagent sales, and a balanced capital allocation strategy.
Fiscal Year 2025
-
Record Q4 revenue and a return to growth in H2 2025 were driven by strong performance in APAC, EMEA, and recurring revenue streams. Despite higher operating expenses and non-cash tax write-offs, liquidity remains strong, and 2026 guidance anticipates continued growth and positive adjusted EBITDA.
-
Double-digit growth continues in most segments, with Asia-Pacific and US markets strong and Europe stabilizing. Aurora Evo adoption is accelerating, reagent revenue is outpacing the market, and comprehensive solutions drive customer loyalty. EMEA challenges are seen as cyclical, with recovery expected.
-
Q3 2025 revenue grew 2% year-over-year to $52.3M, led by APAC and recurring revenue, while EMEA declined sharply. Adjusted EBITDA fell to $2.5M, and net loss was $5.5M. Full-year guidance of $196–$205M was reaffirmed, with strong APAC and recurring revenue momentum expected.
-
Despite market headwinds, FSP instrument volumes grew 3% and recurring revenues rose 18% year-over-year. Aurora Evo launched with pharma-focused features, while Asia-Pacific and reagent businesses drive growth. High incremental margins position the company for strong profitability as the market recovers.
-
Panelists highlighted breakthroughs in proteomics and flow cytometry, enabling new research and clinical applications. Strategic focus on technology validation, flexible sales, and AI-driven innovation supports growth despite market challenges.
-
Q2 2025 revenue declined 2.2% year-over-year to $45.6M, with strong recurring revenue growth offsetting product weakness in EMEA and APAC. Full-year guidance narrowed to $196M–$205M, and new product launches and expanding recurring revenue streams position the company for long-term growth.
-
Service and Asia Pacific businesses are driving growth, while recurring revenue is set to increase significantly. Operational efficiency, regional manufacturing, and the expanding Cytek Cloud platform support strong margins and customer retention. Recent product launches and positive cash flow position the company for continued outperformance.
-
First quarter 2025 revenue declined 7.6% year-over-year to $41.5 million, with strong service and APAC growth offset by weaker U.S. and EMEA instrument sales. Full-year guidance was revised to $196–$210 million, with growth expected in the second half as recurring revenue gains importance.
-
A leading flow cytometry technology provider reported strong 2024 financials, with 77% EBITDA growth, expanding recurring revenue, and global market share gains. Strategic investments in R&D, manufacturing, and AI position the company for continued growth and operational efficiency.
-
Cytek has established itself as a leader in full spectral flow cytometry, driving industry transformation with innovative technology and a growing global customer base. The company remains profitable, invests in R&D, and pursues both organic and strategic growth, with a strong focus on operational efficiency and expanding recurring revenue.
Fiscal Year 2024
-
2024 revenue grew 4% to $200.5M, with strong service and international growth, and adjusted EBITDA up 77%. 2025 guidance is $204–$212M, reflecting headwinds from NIH funding, export controls, and tariffs, but expects continued service momentum and APAC strength.
-
Revised summary: Full Spectrum Profiling technology enables high-dimensional cell analysis, driving industry adoption and attracting global pharma and biotech customers. The Luminex acquisition improved imaging and service margins. Recurring revenue from reagents and services is growing, and gross margins have increased as the company outpaces market growth.
-
The event highlighted strong global growth, robust financials, and leadership in full spectrum flow cytometry, with expanding clinical and bioinformatics offerings. Strategic M&A and operational efficiency support continued innovation and market share gains, especially in pharma and APAC.
-
Full Spectral Profiling technology underpins strong global growth, with over 2,800 instruments deployed and a focus on profitable expansion. APAC and Europe outpace the U.S. due to academic funding, while pharma drives global standardization. R&D and acquisitions support continued leadership.
-
Q3 2024 saw 7% year-over-year revenue growth to $51.5M, with strong international and service revenue gains, positive net income, and robust cash reserves. Full-year guidance was reaffirmed, with continued focus on profitability and global expansion.
-
Achieved 5% growth in H1 2024, outperforming the market despite U.S. softness, with strong gains in EMEA and APAC. Product innovation, successful acquisitions, and digital initiatives drive differentiation, while clinical and reagent segments show promising growth. Revenue is expected to remain seasonally weighted, with global expansion and new products supporting future growth.
-
Panelists highlighted rapid innovation in spatial biology, proteomics, and imaging, with early-stage adoption cycles and significant unmet clinical needs. Market opportunities are large and global, driven by advances in multiplexing, automation, and AI-powered analysis.
-
Q2 2024 revenue rose 4% sequentially but fell 6% year-over-year, with strong EMEA and APAC growth offset by U.S. weakness. Service revenue and margins improved, while full-year guidance was narrowed to 5–9% growth. Net loss widened due to tax and FX impacts.
-
Organic growth surged to 11% in Q1 2024, driven by strong service and instrument demand. Full spectrum flow cytometry is now the industry standard, with expanding cloud and reagent offerings. Financial outlook remains positive, with improved margins and a focus on profitability and cash flow.